Innovative Drug Giant Haisco(002653.SZ)While securing a hefty order worth over 5 billion yuan, the first-quarter earnings forecast is positive.
On the evening of April 12, Haisco announced that it had entered into an exclusive license agreement with AbbVie Group Holdings Ltd. ("AbbVie"), granting AbbVie the exclusive rights to develop, manufacture, and commercialize the Nav1.8 project globally, excluding mainland China, the Hong Kong Special Administrative Region, and the Macao Special Administrative Region.
As part of the consideration for the outbound licensing deal, the company will receive an upfront payment of $30 million and potential additional milestone payments of up to $715 million (approximately RMB 5.087 billion) from AbbVie for the Nav1.8 project license fee. AbbVie will also support a certain amount of research and development costs for the licensed Nav1.8 inhibitor candidate through clinical proof-of-concept under the collaboration.
AbbVie is a global biopharmaceutical company focused on research and development, founded in 2013.Year, spun off from Abbott, headquartered in Illinois, USA, currently has approximately 57,000 employees worldwide. AbbVie's key areas of focus include immunology, oncology, and neurology.Science, as well as the products and services under Allergan Aesthetics.
According to the introduction, the licensed projects HSK55718 and HSK51155 are different selective Nav1.8 blockers. By selectively blocking specific sodium ion channels, they inhibit abnormal discharges of sensory nerves, reducing pain signal transmission at the source, and are intended for the development of pain-related indications. Among them, the HSK55718 molecule is being developed as an intravenous formulation and is currently in Phase I clinical trials in China; the HSK51155 molecule is being developed as an oral formulation and is currently in the preclinical stage.
Haisco stated that the signing of this agreement will further promote the development and commercialization process of HSK55718 and HSK51155 worldwide. This move is an important step for the company to deepen its global presence and accelerate the transformation of innovative achievements. The signing of this agreement is expected to have a positive impact on the company's future performance and enhance its profitability.
After facing performance pressure in 2025, Haisco's performance has surged significantly this year. On April 12, the earnings forecast for the first quarter of 2026 released by Haisco showed that the net profit attributable to shareholders of the listed company is expected to be between 477 million yuan and 557 million yuan during the reporting period, representing a year-on-year increase of 923.34% to 1094.97%. Based on the minimum net profit, this figure is approximately twice the net profit for the whole year of 2025. On the same day, the company's 2025 annual report revealed that its net profit last year was about 260 million yuan, a year-on-year decrease of 34%..36%。
Haisco stated that the growth in performance in the first quarter of this year was mainly due to two aspects: First, the sales of the company's innovative drugs continued to maintain good growth; Second, in January 2026, Haisco authorized the overseas development, production, and commercialization rights of HSK39004 to AirNexis Therapeutics, Inc. for an upfront payment of $108 million and potential additional milestone payments of up to $955 million, along with royalties. During the reporting period, the company received all the cash and part of the equity (according to the equity delivery schedule) from the aforementioned upfront payment and recognized it as revenue.
For2025Haisco Pharmaceutical Group's annual performance declined, and the company stated that the decrease in net profit attributable to shareholders was mainly due to reasons such as a reduction in government subsidies received during the reporting period compared to the same period last year. The annual report shows that government subsidies recorded as current income for 2025 amounted to 124 million yuan, a significant drop from 195 million yuan the previous year. Additionally, Haisco's R&D investment in 2025 reached 1.085 billion yuan, accounting for 24.72% of its revenue. Of this, 804 million yuan was expensed R&D investment, representing a year-on-year increase of 28.87%.
Haisco stated that in 2026, the company will continue to increase R&D investment, relying on the newly established macromolecular platform to conduct biopharmaceutical research, covering monoclonal antibodies/bispecific antibodies/multi-specific antibodies, ADCs, etc., with plans for a significant increase in annual R&D investment. The company’s marketing efforts for the year will comprehensively focus on academic marketing and brand building, promoting Sishuning, Sishujing, Simening, and Bei...ChangpingThe in-hospital sales of products such as [product names], are expected to achieve annual sales revenue growth of over 20% year-on-year.
Tianyancha APP shows that Haisco Pharmaceutical Group was established in August 2005 and went public on January 17, 2012. The company mainly focuses on new drug research and development, production, manufacturing, and sales, concentrating on disease areas such as anesthesia and analgesia, respiratory, chronic diseases, oncology, and autoimmune diseases. Its main products include innovative drugs like Ciprofol Injection, Clilagabalin Besylate Capsules, Cogrelitin Tablets, and Anruikafen Injection.
As of the time of reporting by The Paper on April 13, Haisco's share price increased by 2.14%, reaching 57.32 yuan per share, with a market value of 64.194 billion yuan.
